BioRN Network e.V. members assembly 2017: Entering a new era of excellence
Heidelberg (D)|The BioRN Network e.V. members came together on December 11th, 2017 to set the future path for the BioRN Network.
The decisions made during the members assembly emanate from extensive work on the thematic focus, strategy and composition of the cluster over the past year. Together with the elections of the Executive Board and the Strategic Advisory Board, the members of the BioRN Network e.V. adopted the new statutes of the association together with new membership fees. Next to the original focus on biotechnology, the BioRN cluster will now also include interface technologies in Medical Technology and Digital Health, paying tribute to the growing coalescing of these three technology fields. The statutes will come into act with the official entry into the register of associations.
The new Executive Board members:
Dr. Gitte Neubauer from Cellzome (a GSK company) in Heidelberg was elected as the new chair of the executive BioRN board. Professor Michael Boutros (DKFZ) will be the new co-Chair of the BioRN board. Professor Meuer (Institute for Immunology, Heidelberg University), the previous chair of the BioRN Network e.V., joins the new BioRN board as ordinary member. The other members of the BioRN board are Dr. André Domin (Technology Park Heidelberg), Dr. Stefan Herr (EMBL Ventures), Dr. Volker Stadler (PEPperPRINT) and Dr. Axel Wiest (Merck KGaA)
The Strategic Advisory Board:
The Strategic Advisory Board was formed as an advisory committee that involves the excellence and expertise of all cluster stakeholders. The following Strategic Advisory Board members were elected:
Dr. Siegfried Bialojan (Ernst & Young GmbH, Mannheim); Dr. Elmar Bourdon (Medical Technology Cluster Mannheim); Prof. Dr. Bernd Bukau (ZMBH, Heidelberg); Dr. Adrian Carter (Boehringer Ingelheim, Ingelheim); Dr. Jürgen Gamer (Apogenix AG, Heidelberg); Dr. Jan Gradel (Sino German Hi Tech Park, Heidelberg); Martin Haag (Roche Diagnostics GmbH, Mannheim); Dr. Wolfgang Niopek (IHK, Heidelberg); Dr. Stefan Simianer (AbbVie, Ludwigshafen); Dr. Martin Raditsch (INNOVECTIS GmbH, Frankfurt); Dr. Christian Tidona (BioMed X GmbH, Heidelberg); Dr. Christoph von Kalle National Center for Tumor Diseases (NCT), Heidelberg; Prof. Dr. Heike Wieland (Sanofi Aventis Deutschland GmbH, Frankfurt)
About BioRN Network e.V.
Biotech Cluster Rhine-Neckar (BioRN) is one of Germany’s leading Life Science Clusters. In the BioRN Network association, approximately 80 institutional partners have joined forces to promote the development of the Rhine-Neckar region to make it one of the strongest locations for medical research and development in Europe with the increasing integration of interface technologies in the areas of biotechnology (biotech), medical technology (medtech), and digital health solutions (digital health). Together with the Heidelberg Technology Park, the association is a shareholder of BioRN Cluster Management GmbH.
Network members are internationally renowned research institutions such as the University of Heidelberg, the Mannheim University of Applied Sciences, the German Cancer Research Center (DKFZ) and the European Molecular Biology Laboratory (EMBL), six global pharmaceutical companies (AbbVie, Boehringer Ingelheim, J&J, Merck, Roche and Sanofi) as well as small and medium-sized life science companies and local public organizations.
In the course of internationalization, BioRN formed an alliance with the bio-medicine clusters of Cambridge (UK), Leuven (Belgium), Maastricht (NL) and Copenhagen (DK) in 2010 (Health Axis Europe, HAE). Main goal is the empowering of innovative forces to strengthen the international competitiveness as well as the creation and coordination of joint projects with the European Union’s support.
Dr. Birgit Rogell
BioRN Network e.V.
Read press release here